Article Text

PDF
RGS1 expression is associated with poor prognosis in multiple myeloma
  1. Jin Roh1,
  2. Su-Jin Shin1,2,
  3. A-Neum Lee3,4,
  4. Dok Hyun Yoon5,
  5. Cheolwon Suh5,
  6. Chan-Jeoung Park6,
  7. Jooryung Huh1,
  8. Chan-Sik Park1,3,4
  1. 1Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  2. 2Department of Pathology, University of Yonsei College of Medicine, Severance Hospital, Seoul, Korea
  3. 3Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  4. 4Cell Dysfunction Research Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  5. 5Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  6. 6Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  1. Correspondence to Dr Chan-Sik Park, Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea; csikpark{at}amc.seoul.kr

Abstract

Aims Multiple myeloma (MM) is an invariably fatal disease with highly heterogeneous outcome. Because of this heterogeneity of MM, risk stratification is crucial for therapeutic decision-making. However, no immunohistochemical prognostic or predictive markers have been established yet. The expression of regulator of G-protein signalling (RGS) proteins, which desensitise G-protein-coupled receptor signalling, has been reported to be associated with the prognosis of various malignancies. Recently, our group demonstrated the importance of RGS1 in chemokine signalling in a human MM cell line and normal plasmablasts. In the present study, we explored the prognostic value of RGS1 expression in patients with MM using immunohistochemistry.

Methods We evaluated RGS1 protein expression in 79 bone marrow biopsies obtained from patients with MM between 2008 and 2010 at Asan Medical Center. Correlations between RGS1 expression and clinicopathological factors were analysed.

Results High RGS1 protein expression was significantly associated with poor overall survival (p=0.005). After an adjusted multivariable analysis, high RGS1 protein expression (p=0.010), high International Myeloma Working Group risk (p=0.003) and high serum lactate dehydrogenase levels (p=0.040) were significantly associated with poor outcomes.

Conclusions RGS1 expression may be a prognostic marker for risk stratification and a promising target for the development of a new MM therapy.

Statistics from Altmetric.com

Footnotes

  • Handling editor Cheok Soon Lee

  • Contributors JR: analysed the data, wrote the paper. S-JS: collected the data. A-NL: performed the immunohistochemical staining. CS and DHY: contributed medical information. C-JP: contributed materials and analysis tools. JH: contributed reagents. C-SP: conceived and designed the study.

  • Funding This work was supported by the National Research Foundation of Korea, grant no 2008-0062286, to C-SP (http://www.nrf.re.kr/) and the Asan Institute for Life Sciences, grant no 2012-527 to C-SP (http://en.ails.amc.seoul.kr/). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

  • Competing interests None declared.

  • Ethics approval Institute Review Board of Asan Medical Center.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.